Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on August 21, 2009. The report discloses the resignation of a principal officer, specifically the Chief Scientific Officer, effective September 30, 2009.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the severance package for the departing executive:
- Severance Pay: $212,500 (gross), equivalent to six months of base salary.
- Health Benefits: Full COBRA premium coverage until March 31, 2010, or until new coverage is obtained.
- Outplacement Services: Reimbursement up to $10,000.
- Waived Repayment: The company waived the right to recover a sign-on bonus and relocation expenses.
Material Changes
The material change reported is the departure of John A. Schmidt, M.D., as Chief Scientific Officer. This represents a change in the company's executive leadership structure.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, market outlook, or general management commentary regarding the company's strategic direction. The document focuses solely on the terms of the executive's departure and the associated compensatory arrangements. No specific risks or contingencies beyond the standard terms of the severance agreement are detailed.
Key Facts for Investor Verification
- John A. Schmidt, M.D., resigned as Chief Scientific Officer effective September 30, 2009.
- Total direct cash severance is $212,500.
- The company is waiving repayment of previously provided sign-on and relocation funds.
- Health benefits will be subsidized for up to seven months post-resignation.
- The filing does not disclose the reason for the resignation or the appointment of a successor.